Treatment options in NLPHL
| Risk group . | Treatment options . |
|---|---|
| Stage IA without risk factors | • Radiotherapy alone • Active surveillance • Anti-CD20 antibody* |
| Early stage | • 2-4 cycles of ABVD ± rituximab + radiotherapy • BR ± Radiotherapy • R-CVP ± radiotherapy • Radiotherapy alone • Active surveillance |
| Advanced stage | • 6 × R-CHOP ± radiotherapy • 4-6 cycles escalated BEACOPP ± radiotherapy (PET guided) • BR ± radiotherapy • R-CVP ± radiotherapy • ABVD ± rituximab ± radiotherapy • Active surveillance |
| Risk group . | Treatment options . |
|---|---|
| Stage IA without risk factors | • Radiotherapy alone • Active surveillance • Anti-CD20 antibody* |
| Early stage | • 2-4 cycles of ABVD ± rituximab + radiotherapy • BR ± Radiotherapy • R-CVP ± radiotherapy • Radiotherapy alone • Active surveillance |
| Advanced stage | • 6 × R-CHOP ± radiotherapy • 4-6 cycles escalated BEACOPP ± radiotherapy (PET guided) • BR ± radiotherapy • R-CVP ± radiotherapy • ABVD ± rituximab ± radiotherapy • Active surveillance |
Anti-CD20 antibodies are inferior to radiotherapy. They should only be considered if radiotherapy is not an option.
BR, bendamustine, rituximab; R-CVP, rituximab, cyclophosphamide, vincristine, prednisone.